Adam Fridhammar

Statistics

Publications

Citations

133

H-Index

Active since

2018

Affiliations

Swedish Institute for Health Economics(Current)

Novo Nordisk (Denmark)

Lund University

Skåne University Hospital

Adam Fridhammar is an author at Swedish Institute for Health Economics specializing in cost-effectiveness analysis, cost-effectiveness comparison, and societal perspective analysis.

ORCID

Publications per year

2018–2022

Publications

Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM

Michael Willis, Adam Fridhammar, Jens Gundgaard et al. · PharmacoEconomics · 2020 · 29 citations · Full text

Pharmacy, Health Sciences, Pharmacoeconomics +17

Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden

Åsa Ericsson, Adam Fridhammar · Journal of Medical Economics · 2019 · 26 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

The implementation of a noninvasive lymph node staging (NILS) preoperative prediction model is cost effective in primary breast cancer

Ida Skarping, Kristoffer Nilsson, Looket Dihge et al. · Breast Cancer Research and Treatment · 2022 · 25 citations · Full text

Medicine, Oncology, Surgery +17

Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes

Åsa Ericsson, Divina Glah, Maria Lorenzi et al. · PLoS ONE · 2018 · 17 citations · Full text

Pharmacy, Endocrinology, Pharmacoeconomics +17

Intraductal papillary mucinous neoplasms of the pancreas – a cost-effectiveness analysis of management strategies for the branch-duct subtype

Linus Aronsson, Daniel Ansari, Bodil Andersson et al. · HPB · 2018 · 15 citations

Medicine, Oncology, Surgery +17

1–5 of 7